Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Trial Sites
Back to Top
Basic Trial Information
Trial Description
Summary
Further Trial Information
Eligibility Criteria
Trial Contact Information
| Phase | Type | Status | Age | Sponsor | Protocol IDs |
|---|---|---|---|---|---|
| Phase III | Biomarker/Laboratory analysis, Treatment | Active | 18 and over | NCI | NCI-2011-01981 E1208, ECOG-E1208, CDR0000657952, U10CA021115, NCT01004978 |
Summary
This randomized phase III trial is studying chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treating patients with liver cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as doxorubicin hydrochloride, mitomycin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoembolization kills tumor cells by carrying drugs directly into the tumor and blocking the blood flow to the tumor. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving chemoembolization together with sorafenib tosylate is more effective than chemoembolization alone in treating patients with liver cancer.
Further Study Information
PRIMARY OBJECTIVE:
I. To compare Progression-Free Survival (PFS) of chemoembolization alone to sorafenib in combination with chemoembolization.
SECONDARY OBJECTIVES:
I. To compare overall survival (OS) of chemoembolization alone to sorafenib in combination with chemoembolization.
II. To evaluate extra-hepatic versus intra-hepatic patterns of failure. III. To determine the rates of toxicity related to Sorafenib in combination with chemoembolization.
TERTIARY OBJECTIVES:
I. To analyze the pharmacogenetic and pharmacokinetic properties of Sorafenib including angiogenesis, monooxygenases, polymorphisms and MDR.
II. ECOG secondary imaging objective: Site vs. Central evaluation of PFS. III. To determine the inter-reader concordance for response characterization at four and eight months by the European Association for the Study of Liver (EASL) criteria.
IV. To determine the value of objective tumor response at four and eight months by the EASL criteria to predict PFS (by RECIST) and OS.
V. To evaluate the effects of intra-hepatic vs. extra-hepatic progression on OS.
OUTLINE: This is a multicenter study. Patients are stratified according to macrovascular intrahepatic portal vein invasion (present vs absent), Child Pugh score (A vs B7), and chemoembolization method (doxorubicin-eluting bead vs conventional). Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive sorafenib tosylate orally (PO) twice daily in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of sorafenib tosylate is reached, patients undergo transarterial chemoembolization (TACE) comprising doxorubicin hydrochloride, mitomycin C, and cisplatin (closed to accrual as of 10/1/2010); conventional chemoembolization comprising doxorubicin hydrochloride only; or chemoembolization comprising doxorubicin-eluting beads. Treatment with TACE repeats approximately every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive placebo PO twice daily in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of placebo is reached, patients undergo TACE as in arm I.
MAINTENANCE THERAPY: After completion of chemoembolization, patients receive sorafenib tosylate or placebo as in arm I and II in the absence of disease progression or unacceptable toxicity. Patients undergo chest, abdomen, and/or pelvis CT scans or MRI at baseline, at 4 and 8 months, and every 2 months thereafter.
Blood and tissue samples may be collected at baseline and periodically during study for pharmacogenetic and pharmacokinetic studies. After completion of study therapy, patients are followed up periodically for 4 years.
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of hepatocellular carcinoma (HCC) according to 1 of the following criteria:
- Histologically confirmed disease
- Liver cirrhosis AND ≥ 1 solid liver lesion > 2 cm with early enhancement and delayed enhancement washout on CT scan or MRI regardless of alpha-fetoprotein levels (AFP)
- AFP > 400 ng/mL AND ≥ 1 solid liver lesion > 2 cm regardless of specific imaging characteristics on CT scan or MRI
- Disease must be limited to the liver
- No clinical or radiographic evidence of extra hepatic HCC
- Portal vein lymphadenopathy is allowed for patients with hepatitis B or C
- Branch portal vein invasion by tumor allowed
- No main portal vein invasion by tumor
- Measurable disease constituting < 50% of liver parenchyma within the past 4 weeks
- Child Pugh score of A or B7 within the past 4 weeks
- No ascites detectable on physical evaluation
- Not a candidate for curative resection, orthotopic liver transplantation, or radiofrequency ablation (RFA)
- ECOG performance status 0-1
- Life expectancy ≥ 3 months
- Platelet count ≥ 50,000/μL
- Total bilirubin ≤ 2.0 mg/dL
- Alkaline phosphatase < 5 times upper limit of normal (ULN)
- AST and ALT < 5 times ULN
- Serum creatinine ≤ 1.5 mg/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Able to swallow pills
- No clinical signs of heart failure
- No NYHA class III or IV heart disease
- No evidence of bleeding diathesis or active gastrointestinal bleeding
- No known HIV positivity
- No other concurrent uncontrolled illness (except hepatitis B or C) including, but not limited to, any of the following:
- Uncontrolled hypertension (i.e., optimally treated baseline BP > 150/90 mm Hg)
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
- Psychiatric illness and/or addictive disorder that would limit compliance with study requirements
- No allergy to iodine or gadolinium contrast that cannot be safely controlled with premedication
- No prior brachytherapy (e.g., yttrium-90 microspheres)
- No prior sorafenib tosylate, chemoembolization, or systemic chemotherapy, including cytotoxic agents or molecularly targeted agents
- Prior attempted curative liver resection allowed
- More than 4 weeks since prior RFA
- No concurrent cytochrome P450 enzyme-inducing drugs
- No concurrent prophylactic G-CSF or GM-CSF
Trial Lead Organizations/Sponsors
National Cancer Institute
| John Kauh |  | Principal Investigator |
Trial Sites
|
|
|
|
| U.S.A. | |||
|
|||
| Alabama | |||
|
|||
| Birmingham | |||
|
|||
| UAB Comprehensive Cancer Center | |||
| Carla I. Falkson | Ph: 205-934-0309 | ||
| Mobile | |||
|
|||
| University of South Alabama Mitchell Cancer Institute | |||
| William R Taylor | Ph: 251-665-8000 | ||
| Email: pfrancisco@usouthal.edu | |||
| Arizona | |||
|
|||
| Tucson | |||
|
|||
| Arizona Cancer Center at UMC Orange Grove | |||
| Thomas D Brown | Ph: 520-626-9008 | ||
| Arizona Cancer Center at University Medical Center North | |||
| Thomas D Brown | Ph: 520-626-9008 | ||
| Arizona Cancer Center at University of Arizona Health Sciences Center | |||
| Thomas D Brown | Ph: 520-626-9008 | ||
| Arkansas | |||
|
|||
| Little Rock | |||
|
|||
| Arkansas Cancer Research Center at University of Arkansas for Medical Sciences | |||
| Rangaswamy Govindarajan | Ph: 501-686-8274 | ||
| Veterans Affairs Medical Center - Little Rock | |||
| Rangaswamy Govindarajan | Ph: 501-686-8274 | ||
| California | |||
|
|||
| Greenbrae | |||
|
|||
| Marin Cancer Institute at Marin General Hospital | |||
| Peter D. Eisenberg | Ph: 415-925-5000 | ||
| Email: info@marinspecialtycare.com | |||
| Los Angeles | |||
|
|||
| USC/Norris Comprehensive Cancer Center and Hospital | |||
| Anthony Boutros El-Khoueiry | Ph: 323-865-0451 | ||
| San Francisco | |||
|
|||
| UCSF Helen Diller Family Comprehensive Cancer Center | |||
| Alan Paul Venook | Ph: 877-827-3222 | ||
| Stanford | |||
|
|||
| Stanford Cancer Center | |||
| Daniel Y Sze | Ph: 650-498-7061 | ||
| Email: clinicaltrials@med.stanford.edu | |||
| Colorado | |||
|
|||
| Aurora | |||
|
|||
| University of Colorado Cancer Center at UC Health Sciences Center | |||
| Stephen Leong | Ph: 720-848-0650 | ||
| Colorado Springs | |||
|
|||
| Memorial Hospital Cancer Center - Colorado Springs | |||
| Robert J Hoyer | Ph: 719-365-2406 | ||
| Denver | |||
|
|||
| Porter Adventist Hospital | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Grand Junction | |||
|
|||
| St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center | |||
| Stephen Leong | Ph: 720-848-0650 | ||
| Connecticut | |||
|
|||
| Hartford | |||
|
|||
| Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Delaware | |||
|
|||
| Newark | |||
|
|||
| Helen F. Graham Cancer Center at Christiana Hospital | |||
| Gregory A. Masters | Ph: 302-733-6227 | ||
| District of Columbia | |||
|
|||
| Washington | |||
|
|||
| Veterans Affairs Medical Center - Washington, DC | |||
| Robert G Wadleigh | Ph: 877-328-2621 | ||
| Florida | |||
|
|||
| Lakeland | |||
|
|||
| Lakeland Regional Cancer Center at Lakeland Regional Medical Center | |||
| Manuel A Molina | Ph: 863-904-1900 | ||
| Georgia | |||
|
|||
| Atlanta | |||
|
|||
| Winship Cancer Institute of Emory University | |||
| John S Kauh | Ph: 404-778-1868 | ||
| Macon | |||
|
|||
| Medical Center of Central Georgia | |||
| Frederick M. Schnell | Ph: 478-633-1226 | ||
| Hawaii | |||
|
|||
| Aiea | |||
|
|||
| Kapiolani Medical Center at Pali Momi | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Honolulu | |||
|
|||
| Cancer Research Center of Hawaii | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Hawaii Medical Center - East | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Kapiolani Medical Center for Women and Children | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| OnCare Hawaii, Incorporated - Kuakini | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| OnCare Hawaii, Incorporated - Lusitana | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Queen's Cancer Institute at Queen's Medical Center | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Kailua | |||
|
|||
| Castle Medical Center | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Lihue | |||
|
|||
| Kauai Medical Clinic | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Idaho | |||
|
|||
| Boise | |||
|
|||
| Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Illinois | |||
|
|||
| Bloomington | |||
|
|||
| St. Joseph Medical Center | |||
| Nguyet A Le-Lindqwister | Ph: 800-793-2262 | ||
| Chicago | |||
|
|||
| John H. Stroger, Jr. Hospital of Cook County | |||
| Thomas E. Lad | Ph: 312-864-6000 | ||
| Robert H. Lurie Comprehensive Cancer Center at Northwestern University | |||
| Al Bowen Benson | Ph: 312-695-1301 | ||
| Email: cancer@northwestern.edu | |||
| University of Chicago Cancer Research Center | |||
| Daniel V Catenacci | Ph: 773-834-7424 | ||
| University of Illinois Cancer Center | |||
| Howard Ozer | Ph: 312-355-3046 | ||
| Eureka | |||
|
|||
| Eureka Community Hospital | |||
| Nguyet A Le-Lindqwister | Ph: 800-793-2262 | ||
| Evanston | |||
|
|||
| St. Francis Hospital | |||
| K. Joseph Philip | Ph: 773-878-8200 | ||
| Galesburg | |||
|
|||
| Galesburg Clinic, PC | |||
| Nguyet A Le-Lindqwister | Ph: 800-793-2262 | ||
| Harvey | |||
|
|||
| Ingalls Cancer Care Center at Ingalls Memorial Hospital | |||
| Thomas M Aquisto | Ph: 708-915-4673 | ||
| Email: clinicaltrials@ingalls.org | |||
| Highland Park | |||
|
|||
| Hematology Oncology Associates of Illinois-Highland Park | |||
| Al Bowen Benson | Ph: 312-695-1301 | ||
| Email: cancer@northwestern.edu | |||
| Hinsdale | |||
|
|||
| Hinsdale Hematology Oncology Associates | |||
| Elyse Cheryl Schneiderman | Ph: 630-654-1790 | ||
| Email: info@hhoaltd.com | |||
| Kankakee | |||
|
|||
| Provena St. Mary's Regional Cancer Center - Kankakee | |||
| Al Bowen Benson | Ph: 312-695-1301 | ||
| Email: cancer@northwestern.edu | |||
| La Grange | |||
|
|||
| La Grange Memorial Hospital | |||
| Renee H. Jacobs | Ph: 630-856-7526 | ||
| Libertyville | |||
|
|||
| North Shore Oncology and Hematology Associates, Limited - Libertyville | |||
| Al Bowen Benson | Ph: 312-695-1301 | ||
| Email: cancer@northwestern.edu | |||
| Maywood | |||
|
|||
| Cardinal Bernardin Cancer Center at Loyola University Medical Center | |||
| Kenneth C. Micetich | Ph: 708-226-4357 | ||
| Niles | |||
|
|||
| Cancer Care and Hematology Specialists of Chicagoland - Niles | |||
| Al Bowen Benson | Ph: 312-695-1301 | ||
| Email: cancer@northwestern.edu | |||
| Normal | |||
|
|||
| BroMenn Regional Medical Center | |||
| Nguyet A Le-Lindqwister | Ph: 800-793-2262 | ||
| Community Cancer Center | |||
| Nguyet A Le-Lindqwister | Ph: 800-793-2262 | ||
| Ottawa | |||
|
|||
| Community Hospital of Ottawa | |||
| Nguyet A Le-Lindqwister | Ph: 800-793-2262 | ||
| Pekin | |||
|
|||
| Cancer Treatment Center at Pekin Hospital | |||
| Nguyet A Le-Lindqwister | Ph: 800-793-2262 | ||
| Peoria | |||
|
|||
| CCOP - Illinois Oncology Research Association | |||
| Nguyet A Le-Lindqwister | Ph: 800-793-2262 | ||
| Illinois CancerCare - Peoria | |||
| Nguyet A Le-Lindqwister | Ph: 800-793-2262 | ||
| Methodist Medical Center of Illinois | |||
| Nguyet A Le-Lindqwister | Ph: 800-793-2262 | ||
| OSF St. Francis Medical Center | |||
| Nguyet A Le-Lindqwister | Ph: 800-793-2262 | ||
| Proctor Hospital | |||
| Nguyet A Le-Lindqwister | Ph: 800-793-2262 | ||
| Peru | |||
|
|||
| Illinois Valley Community Hospital | |||
| Nguyet A Le-Lindqwister | Ph: 800-793-2262 | ||
| River Forest | |||
|
|||
| West Suburban Center for Cancer Care | |||
| Isoken Koko | Ph: 708-488-0882 | ||
| Rockford | |||
|
|||
| Swedish-American Regional Cancer Center | |||
| Harvey Eric Einhorn | Ph: 815-489-4413 | ||
| Skokie | |||
|
|||
| Hematology Oncology Associates - Skokie | |||
| Al Bowen Benson | Ph: 312-695-1301 | ||
| Email: cancer@northwestern.edu | |||
| Kansas | |||
|
|||
| Hays | |||
|
|||
| Hays Medical Center | |||
| Peter J. VanVeldhuizen | Ph: 800-525-1483 | ||
| Hutchinson | |||
|
|||
| Hutchinson Hospital Corporation | |||
| Peter J. VanVeldhuizen | Ph: 800-525-1483 | ||
| Kansas City | |||
|
|||
| Kansas City Cancer Centers - West | |||
| Peter J. VanVeldhuizen | Ph: 800-525-1483 | ||
| Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center | |||
| Peter J. VanVeldhuizen | Ph: 800-525-1483 | ||
| Overland Park | |||
|
|||
| Kansas City Cancer Centers - Southwest | |||
| Peter J. VanVeldhuizen | Ph: 800-525-1483 | ||
| Pittsburg | |||
|
|||
| Mount Carmel Regional Cancer Center | |||
| Peter J. VanVeldhuizen | Ph: 800-525-1483 | ||
| Salina | |||
|
|||
| Tammy Walker Cancer Center at Salina Regional Health Center | |||
| Peter J. VanVeldhuizen | Ph: 800-525-1483 | ||
| Shawnee Mission | |||
|
|||
| Kansas City Cancer Center - Shawnee Mission | |||
| Peter J. VanVeldhuizen | Ph: 800-525-1483 | ||
| Topeka | |||
|
|||
| St. Francis Comprehensive Cancer Center | |||
| Peter J. VanVeldhuizen | Ph: 800-525-1483 | ||
| Kentucky | |||
|
|||
| Lexington | |||
|
|||
| University of Kentucky Chandler Medical Center | |||
| John J Rinehart | Ph: 859-257-3379 | ||
| Louisiana | |||
|
|||
| New Orleans | |||
|
|||
| Ochsner Cancer Institute at Ochsner Clinic Foundation | |||
| Jyotsna Fuloria | Ph: 888-562-4763 | ||
| Shreveport | |||
|
|||
| Feist-Weiller Cancer Center at Louisiana State University Health Sciences | |||
| Glenn M. Mills | Ph: 318-813-1412 | ||
| Maryland | |||
|
|||
| Baltimore | |||
|
|||
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |||
| Jean-Francois (Jeff) H Geschwind | Ph: 410-955-8804 | ||
| Email: jhcccro@jhmi.edu | |||
| St. Agnes Hospital Cancer Center | |||
| Carole Miller | Ph: 410-368-2910 | ||
| Massachusetts | |||
|
|||
| Boston | |||
|
|||
| Tufts Medical Center Cancer Center | |||
| Kevin P Daly | Ph: 617-636-5000 | ||
| Email: ContactUsCancerCenter@TuftsMedicalCenter.org | |||
| Burlington | |||
|
|||
| Lahey Clinic Medical Center - Burlington | |||
| Keith Ellis Stuart | Ph: 781-744-8027 | ||
| Michigan | |||
|
|||
| Ann Arbor | |||
|
|||
| University of Michigan Comprehensive Cancer Center | |||
| Paula M Novelli | Ph: 800-865-1125 | ||
| Flint | |||
|
|||
| Genesys Hurley Cancer Institute | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Kalamazoo | |||
|
|||
| West Michigan Cancer Center | |||
| Raymond Sterling Lord | Ph: 269-373-7458 | ||
| Livonia | |||
|
|||
| St. Mary Mercy Hospital | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Marquette | |||
|
|||
| Upper Michigan Cancer Center at Marquette General Hospital | |||
| Amy Weise | Ph: 313-576-9363 | ||
| Saginaw | |||
|
|||
| Seton Cancer Institute at Saint Mary's - Saginaw | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Southfield | |||
|
|||
| Providence Hospital - Southfield | |||
| Anibal Drelichman | Ph: 248-849-5337 | ||
| Email: jaswinder.grewal@stjohn.org | |||
| Minnesota | |||
|
|||
| Minneapolis | |||
|
|||
| Virginia Piper Cancer Institute at Abbott - Northwestern Hospital | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Robbinsdale | |||
|
|||
| Humphrey Cancer Center at North Memorial Outpatient Center | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Saint Paul | |||
|
|||
| Regions Hospital Cancer Care Center | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| United Hospital | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Waconia | |||
|
|||
| Ridgeview Medical Center | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Mississippi | |||
|
|||
| Jackson | |||
|
|||
| University of Mississippi Cancer Clinic | |||
| Louis V Puneky | Ph: 601-815-6700 | ||
| Missouri | |||
|
|||
| Kansas City | |||
|
|||
| Kansas City Cancer Centers - North | |||
| Peter J. VanVeldhuizen | Ph: 800-525-1483 | ||
| Kansas City Cancer Centers - South | |||
| Peter J. VanVeldhuizen | Ph: 800-525-1483 | ||
| Truman Medical Center - Hospital Hill | |||
| Peter J. VanVeldhuizen | Ph: 800-525-1483 | ||
| Veterans Affairs Medical Center - Kansas City | |||
| Suman Kambhampati | Ph: 800-525-1483 | ||
| Lee's Summit | |||
|
|||
| Kansas City Cancer Centers - East | |||
| Peter J. VanVeldhuizen | Ph: 800-525-1483 | ||
| Saint Louis | |||
|
|||
| Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis | |||
| Benjamin R Tan | Ph: 800-600-3606 | ||
| Email: info@siteman.wustl.edu | |||
| Nebraska | |||
|
|||
| Omaha | |||
|
|||
| Methodist Estabrook Cancer Center | |||
| Robert M. Langdon | Ph: 402-354-5144 | ||
| Nevada | |||
|
|||
| Reno | |||
|
|||
| Renown Institute for Cancer at Renown Regional Medical Center | |||
| Christos A Galanopoulos | Ph: 775-982-4400 | ||
| New Hampshire | |||
|
|||
| Lebanon | |||
|
|||
| Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center | |||
| Margit M McGowan | Ph: 800-639-6918 | ||
| Email: cancer.research.nurse@dartmouth.edu | |||
| New Jersey | |||
|
|||
| Newark | |||
|
|||
| UMDNJ University Hospital | |||
| Lillian F. Pliner | Ph: 732-235-8675 | ||
| New York | |||
|
|||
| Brooklyn | |||
|
|||
| Veterans Affairs Medical Center - Brooklyn | |||
| Andrea Nadine Wiesel Leaf | Ph: 800-877-6976 | ||
| New York | |||
|
|||
| Beth Israel Medical Center - Petrie Division | |||
| Peter Kozuch | Ph: 212-844-6286 | ||
| New York University Medical Center | |||
| George Miller | Ph: 212-263-4434 | ||
| Email: prmc.coordinator@nyumc.org | |||
| St. Luke's - Roosevelt Hospital Center - St.Luke's Division | |||
| Peter Kozuch | Ph: 212-844-6286 | ||
| Veterans Affairs Medical Center - New York | |||
| Harold S Ballard | Ph: 212-263-4434 | ||
| Email: prmc.coordinator@nyumc.org | |||
| North Carolina | |||
|
|||
| Chapel Hill | |||
|
|||
| Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill | |||
| Bert H. O'Neil | Ph: 877-668-0683 | ||
| Charlotte | |||
|
|||
| Presbyterian Cancer Center at Presbyterian Hospital | |||
| Justin P Favaro | Ph: 704-384-5369 | ||
| Winston-Salem | |||
|
|||
| Wake Forest University Comprehensive Cancer Center | |||
| Perry Shen | Ph: 336-713-6771 | ||
| Ohio | |||
|
|||
| Cincinnati | |||
|
|||
| University of Cincinnati | |||
| Olugbenga Olowokure (Gbenga) | Ph: 513-558-4553 | ||
| Email: uchealthnews@uc.edu | |||
| Cleveland | |||
|
|||
| MetroHealth Cancer Care Center at MetroHealth Medical Center | |||
| Bruce J. Averbook | Ph: 216-778-8526 | ||
| Email: kbauchens@metrohealth.org | |||
| Columbus | |||
|
|||
| Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center | |||
| Carl R Schmidt | Ph: 866-627-7616 | ||
| Email: osu@emergingmed.com | |||
| Sylvania | |||
|
|||
| Flower Hospital Cancer Center | |||
| Rex B Mowat | Ph: 517-265-0116 | ||
| Toledo | |||
|
|||
| St. Anne Mercy Hospital | |||
| Rex B Mowat | Ph: 517-265-0116 | ||
| Oklahoma | |||
|
|||
| Oklahoma City | |||
|
|||
| Oklahoma University Cancer Institute | |||
| Carla Kurkjian | Ph: 405-271-4272 | ||
| Email: julie-traylor@ouhsc.edu | |||
| Oregon | |||
|
|||
| Glesham | |||
|
|||
| Legacy Mount Hood Medical Center | |||
| Ian D Schnadig | Ph: 503-692-2032 | ||
| Portland | |||
|
|||
| Legacy Emanuel Hospital and Health Center and Children's Hospital | |||
| Ian D Schnadig | Ph: 503-692-2032 | ||
| Legacy Good Samaritan Hospital & Comprehensive Cancer Center | |||
| Ian D Schnadig | Ph: 503-692-2032 | ||
| Tualatin | |||
|
|||
| Legacy Meridian Park Hospital | |||
| Ian D Schnadig | Ph: 503-692-2032 | ||
| Pennsylvania | |||
|
|||
| Danville | |||
|
|||
| Geisinger Cancer Institute at Geisinger Health | |||
| Samir A Kheiri | Ph: 570-271-5251 | ||
| Philadelphia | |||
|
|||
| Albert Einstein Cancer Center | |||
| John Leighton | Ph: 215-456-3880 | ||
| Fox Chase Cancer Center - Philadelphia | |||
| Crystal S Denlinger | Ph: 215-728-4790 | ||
| Kimmel Cancer Center at Thomas Jefferson University - Philadelphia | |||
| Susan J Littman | Ph: 215-955-6084 | ||
| South Carolina | |||
|
|||
| Anderson | |||
|
|||
| AnMed Cancer Center | |||
| Charles E Bowers | Ph: 800-486-5941 | ||
| Charles E Bowers | Ph: 800-486-5941 | ||
| Charleston | |||
|
|||
| Hollings Cancer Center at Medical University of South Carolina | |||
| Melanie B Thomas | Ph: 843-792-9321 | ||
| Spartanburg | |||
|
|||
| CCOP - Upstate Carolina | |||
| Charles E Bowers | Ph: 800-486-5941 | ||
| Gibbs Regional Cancer Center at Spartanburg Regional Medical Center | |||
| Charles E Bowers | Ph: 800-486-5941 | ||
| Tennessee | |||
|
|||
| Jackson | |||
|
|||
| West Tennessee Cancer Center at Jackson-Madison County General Hospital | |||
| Brion V Randolph | Ph: 731-425-6865 | ||
| Knoxville | |||
|
|||
| U.T. Medical Center Cancer Institute | |||
| Wahid T. Hanna | Ph: 865-544-9773 | ||
| Texas | |||
|
|||
| Amarillo | |||
|
|||
| Harrington Cancer Center | |||
| Stewart Allen Sharp | Ph: 806-359-4673 | ||
| Email: ryokubaitis@harringtoncc.org | |||
| Galveston | |||
|
|||
| University of Texas Medical Branch | |||
| Maurice Willis | Ph: 409-772-1950 | ||
| Email: clinical.research@utmb.edu | |||
| Utah | |||
|
|||
| Salt Lake City | |||
|
|||
| Huntsman Cancer Institute at University of Utah | |||
| Ryan G O'Hara | Ph: 801-581-4477 | ||
| Email: clinical.trials@hci.utah.edu | |||
| Virginia | |||
|
|||
| Richmond | |||
|
|||
| Veterans Affairs Medical Center - Richmond | |||
| Rosemarie Mannino | Ph: 804-675-5646 | ||
| Virginia Commonwealth University Massey Cancer Center | |||
| Andrew Poklepovic | Ph: 804-628-1939 | ||
| Washington | |||
|
|||
| Seattle | |||
|
|||
| CCOP - Virginia Mason Research Center | |||
| Craig R. Nichols | Ph: 503-215-6412 | ||
| Group Health Central Hospital | |||
| Gary E Goodman | Ph: 206-386-2323 | ||
| Email: patra.grevstad@swedish.org | |||
| Virginia Mason Medical Center | |||
| Craig R. Nichols | Ph: 503-215-6412 | ||
| Vancouver | |||
|
|||
| Legacy Salmon Creek Medical Center | |||
| Ian D Schnadig | Ph: 503-692-2032 | ||
| Wisconsin | |||
|
|||
| Marshfield | |||
|
|||
| Marshfield Clinic - Marshfield Center | |||
| Kristin M. Gerndt | Ph: 715-389-4457 | ||
| Milwaukee | |||
|
|||
| Froedtert Hospital and Medical College of Wisconsin | |||
| Lauren A Wiebe | Ph: 414-805-4380 | ||
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01004978
Information obtained from ClinicalTrials.gov on March 26, 2013
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top
